Efficacy and safety of empagliflozin combined with metformin (jardiance DUO) in glycemic control of patients with type 2 diabetes mellitus
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by insulin resistance and progressive β-cell dysfunction, resulting in persistent hyperglycemia. Metformin, the first-line drug for T2DM treatment, is often insufficient to maintain long-term glycemic control, requiring combination therapy with other antihyperglycemic agents. Among the new therapeutic options, empagliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, stands out for its additional benefits on body weight, blood pressure, and cardiovascular and renal function. Therefore, this study aimed to analyze scientific evidence published over the last ten years regarding the efficacy and safety of the empagliflozin/metformin combination (Jardiance Duo) in glycemic control of patients with T2DM. This is an integrative literature review conducted in the PubMed, SciELO, ScienceDirect, and Scopus databases, including articles published between 2015 and 2025. A total of 11 studies met the eligibility criteria. The findings showed that the combined therapy promotes significant reductions in glycated hemoglobin (HbA1c), improved glycemic control, and additional metabolic benefits, with a favorable safety profile and low incidence of severe adverse events. In conclusion, the empagliflozin/metformin combination is effective, safe, and cost-effective, representing a promising therapeutic strategy for the management of type 2 diabetes mellitus and aligned with current national and…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.